AstraZeneca Says Imfinzi Studies Cut Death Risk by 58% and 42%
AstraZeneca said two phase 3 studies showed Imfinzi cut death risk by 58% and 42% in lung and bladder cancer, respectively.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.